Evidence map›Paper›PMID 31794601›Full record

GuidelineBlood advances2019

American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.

Robert I Liem, Sophie Lanzkron, Thomas D Coates, Laura DeCastro, Ankit A Desai, Kenneth I Ataga, Robyn T Cohen, Johnson Haynes, Ifeyinwa Osunkwo, Jeffrey D Lebensburger and 8 more

Erratum issuedAbstract readGuidelineHistorical Article
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 85 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Robert I LiemDivision of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
Sophie LanzkronDivision of Adult Hematology, School of Medicine, Johns Hopkins University, Baltimore, MD.
Thomas D CoatesDivision of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, CA.
Laura DeCastroDivision of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Ankit A DesaiKrannert Institute of Cardiology, School of Medicine, Indiana University, Indianapolis, IN.
Kenneth I AtagaCenter for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN.
Robyn T CohenDivision of Pediatric Pulmonary and Allergy, Boston Medical Center, School of Medicine, Boston University, Boston, MA.
Johnson HaynesDivision of Pulmonary Disease, College of Medicine, University of South Alabama, Mobile, AL.
Ifeyinwa OsunkwoDivision of Hematology, The Levine Cancer Institute, Atrium Health, Charlotte, NC.
Jeffrey D LebensburgerDivision of Pediatric Hematology/Oncology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
James P LashDivision of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.
Theodore WunDivision of Hematology and Oncology, School of Medicine, University of California Davis, Sacramento, CA.
Madeleine VerhovsekDivision of Hematology and Thromboembolism, McMaster University, Hamilton, ON, Canada.
Elodie OntalaMilwaukee, WI.
Rae BlaylarkMinneapolis, MN.
Fares AlahdabDivision of General Internal Medicine, Mayo Medical School, Rochester, MN; and.
Abdulrahman KatabiDivision of General Internal Medicine, Mayo Medical School, Rochester, MN; and.
Reem A MustafaDivision of Nephrology and Hypertension, School of Medicine, University of Kansas, Kansas City, KS.

Funding

Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular TachycardiaR01HL136603 · NHLBI · UNIVERSITY OF ARIZONA · PI DESAI, ANKIT A · 2017 to 2021
$2.4M
NHLBI NIH HHS R01 HL136603
6 · The paper itself

Abstract

backgroundPrevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals.

objectiveThese evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD.

methodsASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment.

resultsThe panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed.

conclusionsMost recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.

Indexed as

Anemia, Sickle CellCardiovascular DiseasesHematologyHistory, 21st CenturyHumansKidney DiseasesLung DiseasesUnited States

Identifiers

PMID31794601
PMCPMC6963257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.